Dr. Steve J. Freedland, MD

Dr. Freedland practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Freedland's NPI, 1760572937, was assigned on October 16, 2006. Dr. Freedland graduated from UC Davis School of Medicine in 1997. Dr. Freedland holds California license A68566.

Dr. Freedland's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Freedland's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center. Dmand AI also links Dr. Freedland to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Freedland practices. Vendor and product names are available with a free account.

Urology is Dr. Freedland's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Freedland is board certified in urology by the American Board of Urology. Dmand AI has Dr. Freedland's licenses on file in 3 states: California, North Carolina and Maryland.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery, kidney stone disease and urinary endoscopy among the conditions Dr. Freedland treats.

CMS data shows 298 Medicare services from Dr. Freedland across 8 procedure codes in 2024, for 197 Medicare patients. Medicare paid $29,435 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 197 Medicare patients who saw Dr. Freedland in 2024. The largest group is 65 to 74, with 94 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 22% are also on Medicaid. Their average risk score is 1.62, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Freedland's median patient age at 75, with 4% women.

In 2024, Dr. Freedland wrote 431 Medicare Part D claims for 129 patients. 83% of them were for generic drugs. CMS names the drug for 345 of them, across 5 drugs with 11 or more claims each, at $76,866 in total drug cost. In 2023, CMS named 440 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Freedland for performance year 2024, reported as part of a group. Dr. Freedland accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Freedland as offering telehealth. CMS counts 29 procedures of prostate resection by Dr. Freedland, more than 90% of the clinicians it reports for that procedure.

Dmand AI links 28 papers to Dr. Freedland, published from 2008 to 2019. 2011 was the busiest year, with 4. The most frequent topics are Prostatic Neoplasms, Biopsy and Prostate-Specific Antigen. Dr. Freedland has published most often in Prostate Cancer Prostatic Dis. Dr. Freedland's most frequent co-authors are Gerald L. Andriole, MD, Roger Scott Rittmaster, MD and Firas Faik Hazem Abdollah, MD.

Dmand AI links Dr. Freedland to 2 clinical trials. Open Payments lists research payments to Dr. Freedland that name 2 trials.

CMS Open Payments shows 853 general payments to Dr. Freedland from 26 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 69% of the total. Pfizer Inc. paid the most, $755,137. It also lists 168 research payments totaling $180,765 from 2016 to 2025, naming 2 clinical trials.

Dr. Freedland graduated from UC Davis School of Medicine in 1997. Dr. Freedland is a member of ASCO.

Dr. Freedland is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.